FiercePharmaAsia—Japan's global first nods; Celgene hands back PD-1; China's copycat invite

Asia Map
Roche, AstraZeneca, Celgene and BeiGene made our news this week. (Google)

Japan's health ministry has sent out global first nods to drugs from Roche, Daiichi Sankyo and AstraZeneca. Two years after penning the licensing deal, Celgene has returned PD-1 tislelizumab to BeiGene along with a $150 million breakup fee. Multinational biopharma companies' older medicines in China are under threat as authorities have made a list of 34 drugs and are offering priority review to drugmakers who develop copycats to them. And more.

1. Look out, Bayer: Roche scores first global nod for targeted cancer drug Rozlytrek

AstraZeneca's COPD triplet Breztri, rival to GSK's Trelegy, nabs first nod from Japan

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Japan’s Ministry of Health, Labor and Welfare handed out at least three global first approvals this week. Roche’s Rozlytrek, a rival to Bayer’s Vitrakvi, has won a Japanese nod to treat patients with NTRK fusion-positive advanced recurrent solid tumors regardless of their locations. A month after being voted down by an FDA cancer advisory committee, Daiichi Sankyo’s FLT3 inhibitor Vanflyta (quizartinib), a challenger to Astellas’ Xospata, has been cleared in Japan for relapsed/refractory FLT3-ITD acute myeloid leukemia. AstraZeneca also secured its first global approval for Breztri Aerosphere, a three-in-one chronic obstructive pulmonary disease inhaler that will go up against GlaxoSmithKline’s Trelegy Ellipta.

2. Celgene hands PD-1 tislelizumab med back to BeiGene, forfeiting $150M

As the Bristol-Myers Squibb merger moves ahead, Celgene has handed back its rights to BeiGene’s PD-1 drug tislelizumab and paid a $150 million termination fee. BeiGene Chief Adviser Eric Hedrick recently said the Chinese biotech “fully" expected that the transfer-back would happen. At that time, he said taking back the rights would have a “marginal” effect on clinical development and a be “modest” financial hit.

3. Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

China’s health authority has published its first list of drugs for which the government is soliciting copycats. To sweeten the deal, those who follow will be put under the drug regulator’s priority review pathway. The 34 drugs cover originators from many foreign pharmas and span a wide range of therapeutic areas. Some prominent names include Teva’s Copaxone, Actelion’s Tracleer and AstraZeneca’s Faslodex.

4. AstraZeneca commits $630M to Korean drug R&D push

AstraZeneca is committing $630 million to R&D in South Korea over the next five years. Outlined in a letter of intent with a Korean trade promotion agency and industry group, AstraZeneca will help with new drug development, offering mentoring for biotech startups and the advance of artificial intelligence and other emerging technologies.

5. Lions Health: China healthcare plus digital tech could equal pharma nirvana

China is turning up an ocean of healthcare data. Some 89% of doctors in China are equipped for telemedicine, 44% of Chinese said they’d prefer a remote doctor visit and 94% of healthcare professionals use digital health tech or tracking apps. That spells opportunity for pharmas that can figure out how to work best within digital healthcare, a Lions Health panel figured.

6. China's Fosun rallies support for a joint bid for Bayer's animal health unit: report

Bayer’s for-sale animal health business has reportedly attracted high interest. China’s Fosun International, parent of Fosun Pharma, is considering teaming up with private equity firms or other investors for a joint offer for the franchise, according to Bloomberg. If successful, the takeover would mark another major deal for Fosun since taking a majority stake in Gland Pharma in 2017.

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.